AIP
REGN icon

ARS Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

ARS Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4M Buy
45,484
+214
+0.5% +$146K 1.24% 27
2026
Q1 		$35M Buy
45,270
+9,825
+28% +$7.52M 1.82% 22
2025
Q4 		$27.4M Buy
35,445
+6,676
+23% +$4.53M 1.6% 21
2025
Q3 		$16.2M Buy
28,769
+7,914
+38% +$4.47M 1.07% 30
2025
Q2 		$10.9M Buy
20,855
+14,378
+222% +$8.02M 0.8% 31
2025
Q1 		$4.61M Sell
6,477
-3
-0% -$2.06K 0.42% 46
2024
Q4 		$4.62M Sell
6,480
-5,540
-46% -$4.65M 0.42% 46
2024
Q3 		$12.6M Buy
12,020
+142
+1% +$158K 1.13% 31
2024
Q2 		$12.5M Sell
11,878
-128
-1% -$124K 1.19% 27
2024
Q1 		$11.6M Buy
+12,006
New +$11.4M 1.15% 28
2022
Q4 		– Sell
-800
Closed -$551K – 174
2022
Q3 		$551K Buy
+800
New +$504K 0.08% 97

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

ARS Investment Partners's REGN Position: Q2 2026 in Review

ARS Investment Partners increased its Regeneron Pharmaceuticals (REGN) stake by 0.47% in Q2 2026, buying an estimated $146K and bringing the position to 45,484 shares worth $28.4M. The position accounts for 1.24% of the portfolio, ranked #27.

ARS Investment Partners first reported a position in REGN in Q3 2022 and has held it in 11 quarters since. The position peaked at $35M in Q1 2026. 298 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • ARS Investment Partners held 45,484 shares of Regeneron Pharmaceuticals worth $28.4M as of Q2 2026.
  • ARS Investment Partners bought 214 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $146K.
  • Regeneron Pharmaceuticals made up 1.24% of ARS Investment Partners's portfolio in Q2 2026, its #27 holding.
  • ARS Investment Partners first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
  • ARS Investment Partners's Regeneron Pharmaceuticals position peaked at $35M in Q1 2026.
  • 298 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on ARS Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.